Brendan Haberle’s practice focuses on technology transactions, within the life sciences, consumer products, and other industries.
Mr. Haberle leverages his training and prior experience in laboratory science and technical analysis to advise companies on technology licensing, collaborations and other strategic intellectual property transactions, as well as regarding intellectual property matters within corporate transactions such as public offerings and mergers and acquisitions.
Mr. Haberle also advises clients on the structuring and negotiation of a broad range of other technology-centric arrangements, such as manufacturing and supply agreements, clinical trial agreements, profit sharing and co-promotion agreements, university licenses, services agreements, and research agreements.
Prior to his legal career, Mr. Haberle worked at Los Alamos National Laboratory and the US government in support of its WMD counter-proliferation and counter-terrorism missions.
Representative clients include:
- Allergan
- Amgen
- Baxter
- Caesars Entertainment
- Castle Creek Pharmaceuticals
- CytomX Therapeutics
- GenesisCare
- Illumina
- Impossible Foods
- Ligand Pharmaceuticals
- Nestlé
- Sobi
- Zentalis Pharmaceuticals
Representative transactions include:
- Amgen in its acquisition of an equity stake in BeiGene as well as a strategic collaboration in which BeiGene will commercialize medicines from Amgen’s oncology pipeline
- Bridge Bio, Inc. in its IPO
- CytomX Therapeutics’ collaboration with Astellas Pharma for the development, and commercialization of novel antibody products for the treatment of cancer
- Ignyta, Inc. in its US$1.7 billion merger with Roche
- Impact Biomedicines in its acquisition by Celgene for up to US$7 billion
- Zentalis Pharmaceuticals, Inc. in its IPO